Sign In
Buy TRVN
$0.0010
+0 (+0%)
At Close: Jun 03, 2026
Trevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened
03:11am, Friday, 03'rd Apr 2026
Trevena, Inc. (NASDAQ: TRVN - Get Free Report)'s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.01 and traded as high as $0.
Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)
02:00am, Thursday, 15'th Jan 2026
Profitability This table compares Trevena and Ampio Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Ampio Ph
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market
04:05pm, Wednesday, 26'th Mar 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 10'th Dec 2024
After losing some value lately, a hammer chart pattern has been formed for Trevena (TRVN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
Trevena Reports Third Quarter 2024 Results and Provides Business Update
07:01am, Thursday, 07'th Nov 2024
CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen
Trevena Announces Receipt of Nasdaq Delisting Notification
04:05pm, Friday, 04'th Oct 2024
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones
What's Going On With Neurological Disease Focused Trevena On Thursday?
12:50pm, Thursday, 20'th Jun 2024
Shares of Trevena Inc TRVN are trading lower on Thursday, with a session volume of 23.65 million, as per data from Benzinga Pro.
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization
Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)
01:09am, Monday, 20'th May 2024
Trevena, Inc. (NASDAQ:TRVN – Free Report) – HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Trevena in a research report issued to clients and investors on Thurs
Trevena Reports First Quarter 2024 Results and Provides Business Update
07:00am, Wednesday, 15'th May 2024
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
07:00am, Monday, 01'st Apr 2024
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
02:00pm, Thursday, 28'th Dec 2023
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
09:10am, Wednesday, 27'th Dec 2023
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of n
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
07:02am, Monday, 04'th Dec 2023
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner
